PerkinElmer
check quantity

PD-L1 (human), lyophilized (LANCE)

Human PD-L1 standard, for use in running standard curves in LANCE Ultra TR-FRET assays. This standard is already provided in the LANCE Ultra Human PD-L1 TR-FRET Detection Kit, but can also be ordered separately.

You successfully added item(s) to your cart

For research use only. Not for use in diagnostic procedures.

Part Number
List Price
Your Price
Quantity
TRF1355S
308.00 USD
more
Buy Now

Please enter valid quantity

Please login to add favorites

NULL OR EMPTY CART

Detail Information

This standard is provided in liquid form (100 µL at 3 µg/mL). The analyte should be used within 60 minutes or aliquoted into screw-capped polypropylene vials and stored at -20°C for further experiments. Avoid multiple freeze-thaw cycles. One vial contains an amount of analyte sufficient for performing 10 standard curves.

Specifications

Assay Target PD-L1
Assay Target Class Protein
Automation Compatible Yes
Detection Method Time-Resolved Fluorescence (TRF), TR-FRET
Experimental Type In vitro
Product Brand Name LANCE Ultra
Shipping Condition Blue Ice
Target Species Human
Therapeutic Area Cancer
Unit Size 1 µg
Resources, Events & More
  • All

Application Note

Measuring PD-L1 and PD-1 Expression in Human Cells with LANCE Ultra TR-FRET

Immuno-oncology is an exciting area within cancer research and among the most promising approaches to activating therapeutic antitumor immunity is through the blockade of immune checkpoints. The programmed cell death-1 (PD-1) immune checkpoint pathway is a negative regulator of T cell immune function. When PD-1 is bound to programmed cell death-ligand 1 (PD-L1), T cell response is suppressed. Many tumor cells escape anti-tumor immunity through their expression of Programmed Death Ligand 1 (PD-L1 or B7-H1), which interacts with T cell-expressed PD-1 and results in T cell apoptosis. PD-L1 expression has been studied in multiple different cancers. While several anti-PD-1 or PD-L1 monoclonal antibodies that block the PD-1/ PD-L1 complex formation have been developed to date, there remains a need for more robust, rapid, high-throughput assays to identify and qualify novel inhibitors of PD-1/PD-L1 binding and assays to detect expression levels of both binding partners. Find out how LANCE® Ultra Technology provides a fast, powerful, homogeneous platform for identifying and characterizing endogenous PD-L1 and PD-1 expression in human cells.

PDF 4 MB

Brochure